EANS-Voting Rights: SYGNIS Pharma AG / Release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of

PR Newswire/euro adhoc/
EANS-Voting Rights: SYGNIS Pharma AG / Release according to article 26, section
1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution
Notification of voting rights transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 
Announcement according to Article 21, Section 1 of the WpHG (share) 
1. BASF SE, Ludwigshafen , Germany has notified us pursuant to section 21 (1)
WpHG (German Securities Trading Act) on December 6, 2012, that its percentage of
voting rights in SYGNIS Pharma AG fell below the threshold of 3 %, 5% and 10% on
December 4, 2012 and amounts to 2.48 % (231,904 voting rights) as per this date. 
2. Mr. Prof. Dr. Friedrich von Bohlen und Halbach, Germany, has notified us
pursuant to section 21 (1) WpHG on December 7, 2012, that his percentage of
voting rights in SYGNIS Pharma AG fell below the threshold of 3 % on December 4,
2012 and amounts to 0.94 % (87,798 voting rights versus to a total amount of
9,349,724 voting rights) as per this date. Of these voting rights, 0.11 % (9,999
voting rights of his children) are to be attributed to him pursuant to section
22 (1) sentence 1 no. 6 WpHG. 
3. Mr. Berthold Wipfler, Germany, has notified us pursuant to section 21 (1)
WpHG on December 7, 2012, that his percentage of voting rights in SYGNIS Pharma
AG fell below the threshold of  50%, 30%, 25%, 20% and 15% on December 4, 2012
and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of
9,349,724 voting rights) as per this date. According to section 22 (1) sentence
1 no. 1 WpHG the voting rights are allocated to Berthold Wipfler. The allocation
is due to the companies controlled by Berthold Wipfler with voting rights of
each company of 3% or more: BW Verwaltungs GmbH, OH-Capital GmbH & Co. KG,
DH-Capital GmbH & Co. KG, OH Beteiligungen GmbH & Co. KG, dievini Hopp BioTech
holding GmbH & Co. KG.  
4. Mr. Oliver Hopp, Germany, has notified us pursuant to section 21 (1) WpHG on
December 7, 2012, that his percentage of voting rights in SYGNIS Pharma AG fell
below the threshold of  50%, 30%, 25%, 20% and 15% on December 4, 2012 and
amounts to 12.27 % (1,146,950 voting rights versus to a total amount of
9,349,724 voting rights) as per this date.
According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are
allocated to Oliver Hopp. The allocation is due to the companies controlled by
Oliver Hopp with voting rights of each company of 3% or more: BW Verwaltungs
GmbH, OH-Capital GmbH & Co. KG, DH-Capital GmbH & Co. KG, OH Beteiligungen GmbH
& Co. KG, dievini Hopp BioTech holding GmbH & Co. KG.  
5. Mr. Dietmar Hopp, Germany, has notified us pursuant to section 21 (1) WpHG on
December 7, 2012, that his percentage of voting rights in SYGNIS Pharma AG fell
below the threshold of  50%, 30%, 25%, 20% and 15% on December 4, 2012 and
amounts to 12.27 % (1,146,950 voting rights versus to a total amount of
9,349,724 voting rights) as per this date.
According to section 22 (1) sentence 1 no. 1 WpHG the voting rights are
allocated to Dietmar Hopp. The allocation is due to the companies controlled by
Dietmar Hopp with voting rights of each company of 3% or more: BW Verwaltungs
GmbH, OH-Capital GmbH & Co. KG, DH-Capital GmbH & Co. KG, OH Beteiligungen GmbH
& Co. KG, dievini Hopp BioTech holding GmbH & Co. KG.  
6. dievini Hopp BioTech holding GmbH & Co.KG, Walldorf, Germany, has notified us
pursuant to section 21 (1) WpHG on December 7, 2012, that its percentage of
voting rights in SYGNIS Pharma AG fell below the threshold of  50%, 30%, 25%,
20% and 15% on December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights
versus to a total amount of 9,349,724 voting rights) as per this date. 
7. DH-Capital GmbH & Co.KG, Wiesloch, Germany, has notified us pursuant to
section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in
SYGNIS Pharma AG fell below the threshold of  50%, 30%, 25%, 20% and 15% on
December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a
total amount of 9,349,724 voting rights) as per this date. According to section
22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to DH-Capital GmbH
& Co.KG. The allocation is due to the companies controlled by DH-Capital GmbH &
Co.KG with voting rights of each company of 3% or more: dievini Hopp BioTech
holding GmbH & Co. KG.  
8. OH Beteiligungen GmbH & Co.KG, Wiesloch, Germany, has notified us pursuant to
section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in
SYGNIS Pharma AG fell below the threshold of  50%, 30%, 25%, 20% and 15% on
December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a
total amount of 9,349,724 voting rights) as per this date. According to section
22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to OH Beteiligungen
GmbH & Co.KG. The allocation is due to the companies controlled by OH
Beteiligungen GmbH & Co.KG with voting rights of each company of 3% or more:
dievini Hopp BioTech holding GmbH & Co. KG.  
9. OH-Capital GmbH & Co.KG, Wiesloch, Germany, has notified us pursuant to
section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in
SYGNIS Pharma AG fell below the threshold of  50%, 30%, 25%, 20% and 15% on
December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a
total amount of 9,349,724 voting rights) as per this date. According to section
22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to OH-Capital GmbH
& Co.KG. The allocation is due to the companies controlled by OH-Capital GmbH &
Co.KG with voting rights of each company of 3% or more: dievini Hopp BioTech
holding GmbH & Co. KG, OH Beteiligungen GmbH & Co. KG. 
10. BW Verwaltungs GmbH, Wiesloch, Germany, has notified us pursuant to section
21 (1) WpHG on December 7, 2012, that its percentage of voting rights in SYGNIS
Pharma AG fell below the threshold of  50%, 30%, 25%, 20% and 15% on December 4,
2012 and amounts to 12.27 % (1,146,950 voting rights versus to a total amount of
9,349,724 voting rights) as per this date. According to section 22 (1) sentence
1 no. 1 WpHG the voting rights are allocated to BW Verwaltungs GmbH. The
allocation is due to the companies controlled by BW Verwaltungs GmbH with voting
rights of each company of 3% or more: dievini Hopp BioTech holding GmbH & Co.
KG, OH Beteiligungen GmbH & Co. KG, DH-Capital GmbH & Co. KG, OH-Capital GmbH &
Co. KG. 
11. DH-Holding GmbH & Co. KG, Wiesloch, Germany, has notified us pursuant to
section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in
SYGNIS Pharma AG fell below the threshold of  50%, 30%, 25%, 20% and 15% on
December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a
total amount of 9,349,724 voting rights) as per this date. According to section
22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to DH-Holding GmbH
& Co. KG. The allocation is due to the companies controlled by DH-Holding GmbH &
Co. KG with voting rights of each company of 3% or more: dievini Hopp BioTech
holding GmbH & Co. KG,, DH-Capital GmbH & Co. KG. 
12. DH-Holding Verwaltungs GmbH, Wiesloch, Germany, has notified us pursuant to
section 21 (1) WpHG on December 7, 2012, that its percentage of voting rights in
SYGNIS Pharma AG fell below the threshold of  50%, 30%, 25%, 20% and 15% on
December 4, 2012 and amounts to 12.27 % (1,146,950 voting rights versus to a
total amount of 9,349,724 voting rights) as per this date. According to section
22 (1) sentence 1 no. 1 WpHG the voting rights are allocated to DH-Holding
Verwaltungs GmbH. The allocation is due to the companies controlled by
DH-Holding Verwaltungs GmbH with voting rights of each company of 3% or more:
dievini Hopp BioTech holding GmbH & Co. KG, DH-Capital GmbH & Co. KG, DH-Holding
GmbH & Co. KG. 
Further inquiry note:
Marc Risch
Telefon: +49 (6221) 454 - 737
E-Mail: Marc.Risch@sygnis.de 
issuer:      SYGNIS Pharma AG 
         Im Neuenheimer Feld 515 
         D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:        contact@sygnis.de
WWW:         http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1RFM03
indexes:     
stockmarkets: 
language:   English 
    
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Dec/07/2012 17:41 GMT